Ropsacitinib

DB18709InvestigationalSmall molecule

Ropsacitinib: Overview.

Mechanism: Pharmacologically active on Non-receptor tyrosine-protein kinase TYK2
Curator reviewed
Formula / weight: C₂₀H₁₇N₉ · 383.419 g/mol (avg)
Also known as: Cyclobutaneacetonitrile, 3-cyano-1-(4-(6-(1-methyl-1h-pyrazol-4- yl)pyrazolo(1,5-a)pyrazin-4-yl)-1h-pyrazol-1-yl)-, trans- · Trans-3-cyano-1-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)- 1h-pyrazol-1-yl)-cyclobutaneacetonitrile
Code names: PF-06826647

Resolves to

Compound

Structure

InChIKeyXPLZTJWZDBFWDE-OYOVHJISSA-NSMILESCN1C=C(C=N1)C1=CN2N=CC=C2C(=N1)C1=CN(N=C1)[C@@]1(CC#N)C[C@@H](C1)C#N

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ropsacitinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.